Rainer-georg Goeldner
Birkendorfer Str. 65
Biberach An Der Riss, BW, Germany
Biberach An Der Riss, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials.
Journal: Journal of psychopharmacology (Oxford, England)
Published: September 02, 2026
NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: April 02, 2026
Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers.
Journal: Journal of psychopharmacology (Oxford, England)
Published: September 12, 2024
Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies.
Journal: British journal of clinical pharmacology
Published: January 09, 2024
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
Journal: Respirology (Carlton, Vic.)
Published: August 23, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
Journal: The European respiratory journal
Published: December 21, 2020
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
Journal: The European respiratory journal
Published: December 16, 2020
The natural history of progressive fibrosing interstitial lung diseases.
Journal: The European respiratory journal
Published: January 15, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Journal: The Lancet. Respiratory medicine
Published: November 18, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Journal: The New England journal of medicine
Published: October 01, 2019
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
Journal: British journal of cancer
Published: June 06, 2019
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.
Journal: British journal of haematology
Published: November 20, 2018
Last Updated: 09/26/2026